華仁藥業(300110.SZ):終止前次籌劃實控人變更事項並再次籌劃實控人變更事項
格隆匯6月21日丨華仁藥業(300110.SZ)公佈,公司於2023年10月26日收到公司間接控股股東西安曲江文化金融控股(集團)有限公司(以下簡稱"曲江金控")的通知,曲江金控於2023年10月25日與陝西醫藥控股集團有限責任公司(以下簡稱"陝藥集團")簽署《大健康領域戰略框架合作協議》,形成籌劃將其所持公司控股股東西安曲江天授大健康投資合夥企業(有限合夥)(以下簡稱"天授大健康")財產份額轉讓給陝藥集團的意向(以下簡稱"前次財產份額轉讓")。
公司於2024年6月20日收到公司間接控股股東曲江金控的通知,由於經各方充分協商溝通後未能就前次財產份額轉讓的具體條件達成一致意見,曲江金控決定終止籌劃前次財產份額轉讓及實際控制人變更事項。
公司於2024年6月20日收到公司間接控股股東曲江金控的通知,為聚焦主業,整合優質資源,緊抓健康中國戰略及產業發展機遇,落實陝西省做大做強做優生物醫藥產業鏈,加快重點產業鏈集羣化發展的目標,曲江金控於2024年6月20日與西安健康醫療集團有限公司(以下簡稱"西安健康集團")簽署《大健康領域戰略框架合作協議》,形成籌劃將其所持公司控股股東天授大健康財產份額轉讓給西安健康集團的意向(以下簡稱"本次財產份額轉讓")。西安健康集團成立於2019年,是西安市國資委為整合市屬健康醫藥產業資源,批覆同意由西安市工業投資集團組建成立的全資子公司。
公司目前控股股東為西安曲江天授大健康投資合夥企業(有限合夥),實際控制人為西安曲江新區管理委員會。若本次財產份額轉讓事項最終完成,可能涉及公司實際控制人由西安曲江新區管理委員會變更為西安市人民政府國有資產監督管理委員會等事宜,公司控股股東沒有變化仍為西安曲江天授大健康投資合夥企業(有限合夥)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.